}}{{Navigation bar|title = Phase III Clinical Trials by Year|list = 2014 – 2015 – 2016 – 2017}}
| compound | cancer type | reference | companies involved | | Abemaciclib | breast cancer, lung cancer |
| Atezolizumab | bladder cancer | Genentech, Roche |
| Alectinib | lung cancer |
| Ruxolitinib | pancreatic cancer |
| Avelumab | non-small-cell lung cancer |
| RHB-104 | gastrointestinal cancer | RedHill Biopharma |
| Vicinium | bladder cancer | Viventia |
| Cetuximab | colorectal cancer |
| eltrapuldencel-T | melanoma | Caladrius Biosciences |
| Panitumumab | colorectal cancer |
| Olaratumab | sarcoma |
| Pertuzumab | breast cancer | Genentech |
| AGS-003 | renal cell carcinoma | Argos Therapeutics[1] |
| Rociletinib | non-small-cell lung cancer |
| Niraparib | ovarian cancer |
| Sunitinib | small-cell lung cancer |
| Pazopanib | ovarian cancer |
| nelipepimut-s | breast cancer |
| Xilonix | colorectal cancer |
| Cabozantinib | prostate cancer |
| Bevacizumab | lung cancer |
| Rucaparib | ovarian cancer | Clovis Oncology |
| Ganetespib | lung cancer |
| Copanlisib | non-Hodgkin lymphoma |
| Palbociclib | breast cancer |
| Selumetinib | melanoma |
| Nivolumab | lung cancer |
| Rigosertib | myelodysplasia |
| Enzalutamide | prostate cancer |
| Pembrolizumab | melanoma |
| regorafenib | colorectal cancer |
| Ipilimumab | prostate cancer |
| neratinib | breast cancer | Puma Biotechnology |
| Vesigenurtacel-L | bladder cancer |
| Masitinib | breast cancer |
| Carfilzomib | multiple myeloma | Amgen |
| Afatinib | non-small cell lung cancer |
| ThermoDox doxorubicin | liver cancer |
| Eribulin | breast cancer | Eisai |
| Bortezomib | myeloma | Millennium Pharmaceuticals |
| Vitamin D | colorectal cancer | Dana-Farber Cancer Institute |
| Ramucirumab | colorectal cancer | Eli Lilly |
| Talimogene laherparepvec | melanoma | Astrazeneca |
| Afatinib | lung cancer |
| Nivolumab | non-small cell lung cancer | Bristol-Myers Squibb |
| Obinutuzumab + chlorambucil | cell lung carcinoma |
| AGS-003 Dentritic cell immunotherapy | renal cell carninoma | Argos |
| Entinostat | breast cancer | Syndax |
| DCVax-L Dentritic cell immunotherapy | glioblastoma | Northwest Biotherapeutics |
| Nabiximols | cancer pain | GW Pharmaceuticals |
| cutirsen sodium | Non-Small Cell Lung Cancer | OncoGenex Pharmaceuticals |
| hepcortespenlisimut-L | hepatocellular carcinoma | Immunitor |
|
1. ^{{Cite journal|last = Staff|date = 15 May 2016|title = Argos Therapeutics Axing 13% of Workforce|url = http://gen.epubxp.com/i/674077-may15-2016/9|journal = Genetic Engineering & Biotechnology News|type = Paper|volume = 36|issue = 10|page = 9|access-date =}}
{{DEFAULTSORT:Phase III Cancer Clinical Trials 2015}}